Target Information

Target General Infomation
Target ID
T65883
Former ID
TTDI02045
Target Name
Claudin 18
Gene Name
CLDN18
Synonyms
Claudin18; CLDN18
Target Type
Clinical Trial
Disease Esophageal cancer [ICD9: 150; ICD10: C15]
Function
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium- independent cell-adhesion activity.
BioChemical Class
Claudin
UniProt ID
P56856
Sequence
MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSVFQYEGLWRSCVRQSSGF
TECRPYFTILGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLT
SGIMFIVSGLCAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWV
AGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKI
YDGGARTEDEVQSYPSKHDYV
Drugs and Mode of Action
Drug(s) Claudiximab Drug Info Phase 2 Esophageal cancer [523164]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cell adhesion molecules (CAMs)
Tight junction
Leukocyte transendothelial migration
Hepatitis C
NetPath Pathway IL4 Signaling Pathway
Reactome Tight junction interactions
References
Ref 523164ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health.
Ref 532444Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.